Identification of Candidates for Longer Lung Cancer Screening Intervals Following a Negative Low-Dose Computed Tomography Result

Journal of the National Cancer Institute

Volumn 111, Issue 9, 2019, Pages 996-999

  Robbins, Hilary A ^a   Berg, Christine D ^b   Cheung, Li C ^b   Chaturvedi, Anil K ^b   Katki, Hormuzd A ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DECISION MAKING; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EMPHYSEMA; FALSE POSITIVE RESULT; FEATURE EXTRACTION; FOLLOW UP; HUMAN; LIFE EXPECTANCY; LOW-DOSE COMPUTED TOMOGRAPHY; LUNG CANCER; LUNG CONSOLIDATION; NON SMALL CELL LUNG CANCER; PATIENT PREFERENCE; PRACTICE GUIDELINE; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; THRESHOLD LIMIT VALUE; VALIDATION STUDY; AGE; CLINICAL DECISION MAKING; EARLY CANCER DIAGNOSIS; FEMALE; HEALTH SURVEY; LUNG TUMOR; MALE; MASS SCREENING; PROCEDURES; RADIATION DOSE; TIME FACTOR; X-RAY COMPUTED TOMOGRAPHY;

AGE FACTORS; CLINICAL DECISION-MAKING; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MASS SCREENING; POPULATION SURVEILLANCE; RADIATION DOSAGE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85069586260     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/JNCI/DJZ041     Document Type: Article

References (28)

1. Aberle DR, Adams AM, Berg CD, et al. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.
2. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307(22):2418–2429.
3. Bach PB. Raising the bar for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160(5):365–366.
4. Kinsinger LS, Anderson C, Kim J, et al. Implementation of lung cancer screening in the Veterans Health Administration. JAMA Intern Med. 2017;177(3): 399–406.
5. de Koning HJ, Meza R, Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160(5): 311–320.
6. Jemal A, Fedewa SA. Lung cancer screening with low-dose computed tomography in the United States– 2010 to 2015. JAMA Oncol. 2017;3(9): 1278–1281.
7. Green AK, Bach P. Model-based eligibility for lung cancer screening: where theory meets practice. Ann Intern Med. 2018;168(3):223–224.
8. Patz EF, Greco E, Gatsonis C, Pinsky P, Kramer BS, Aberle DR. Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial. Lancet Oncol. 2016;17(5):590–599.
9. Tammemagi MC, Schmidt H, Martel S, et al. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study. Lancet Oncol. 2017;18(11):1523–1531.
10. Horeweg N, van Rosmalen J, Heuvelmans MA, et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet Oncol. 2014; 15(12):1332–1341.
11. van der Aalst CM, Ten Haaf K, de Koning HJ. Lung cancer screening: latest developments and unanswered questions. Lancet Respir Med. 2016;4(9): 749–761.
12. Field JK, Duffy SW. Lung cancer CT screening: is annual screening necessary? Lancet Oncol. 2016;17(5):543–544.
13. Karachaliou N, Sosa AE, Rosell R. Annual or biennial lung cancer CT screening? J Thorac Dis. 2016;8(9):2424–2426.
14. Ridge CA, Boiselle PM. Optimizing the lung cancer screening interval: the world is waiting. J Thorac Dis. 2016;8(10):E1369–E1370.
15. Kavanagh J, Liu G, Menezes R, et al. Importance of long-term low-dose CT follow-up after negative findings at previous lung cancer screening. Radiology. 2018;289(1):218–224.
16. Schreuder A, Schaefer-Prokop CM, Scholten ET, Jacobs C, Prokop M, van Ginneken B. Lung cancer risk to personalise annual and biennial follow-up computed tomography screening. Thorax. 2018;73:626–633.
17. McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med. 2013;369(10): 910–919.
18. Katki HA, Kovalchik SA, Berg CD, Cheung LC, Chaturvedi AK. Development and validation of risk models to select ever-smokers for CT lung cancer screening. JAMA. 2016;315(21):2300–2311.
19. National Cancer Institute. Lung cancer risk assessment tool. https://analysistools.nci.nih.gov/lungCancerRiskAssessment/. Accessed April 17, 2018.
20. Diggle P, Heagerty P, Liang KY, Zeger S. Chapter 10: Transition models. In: Atkinson AC, Carroll RJ, Hand DJ, Wang J-L, eds. Analysis of Longitudinal Data. 2nd ed. 2013. Oxford, UK: Oxford University Press.
21. Wacholder S. Binomial regression in GLIM: estimating risk ratios and risk differences. Am J Epidemiol. 1986;123(1):174–184.
22. Caverly TJ, Cao P, Hayward RA, Meza R. Identifying patients for whom lung cancer screening is preference-sensitive: a microsimulation study. Ann Intern Med. 2018;169(1):1–9.
23. Moyer VA. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(5):330–338.
24. Cheung LC, Katki HA, Chaturvedi AK, Jemal A, Berg CD. Preventing lung cancer mortality by computed tomography screening: the effect of risk-based versus U.S. Preventive Services Task Force eligibility criteria, 2005-2015. Ann Intern Med. 2018;168(3):229–232.
25. Ten Haaf K, de Koning HJ. Overdiagnosis in lung cancer screening: why modelling is essential. J Epidemiol Community Health. 2015;69(11): 1035–1039.
26. Horeweg N, van der Aalst CM, Thunnissen E, et al. Characteristics of lung cancers detected by computed tomography screening in the randomized NELSON trial. Am J Respir Crit Care Med. 2013;187(8):848–854.
27. Yousaf-Khan U, van der Aalst C, de Jong PA, et al. Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval. Thorax. 2017;72(1):48–56.
28. Sverzellati N, Silva M, Calareso G, et al. Low-dose computed tomography for lung cancer screening: comparison of performance between annual and biennial screen. Eur Radiol. 2016;26(11):3821–3829.